Clinical trial
A Randomized, Cross-over, Placebo-controlled, Double-blind, Single-center, Phase II Study of Cetuximab in Patients With Treatment-refractory, Non-malignant Severe Chronic Neuropathic Pain
NCT02490436 is registered in ClinicalTrials.gov with Sorlandet Hospital HF as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Cross-over, Placebo-controlled, Double-blind, Single-center, Phase II Study of Cetuximab in Patients With Treatment-refractory, Non-malignant Severe Chronic Neuropathic Pain
- Lead sponsor
- Sorlandet Hospital HF
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- October 31, 2015
- Completion date
- October 31, 2016
- Enrollment
- 15 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.